Storas AH, Fossa SD, Ursin G, et al. - The outcomes revealed that in Norway, the median overall (OS) of prostate cancer with distant metastases (mPCa) has elevated by one year since 2004 for mPCa patients. The results indicated that survival improvement persisted after adjustment for recognized prognostic factors and may be related to the introduction of new drugs in Norway.

• Researchers evaluated survival in 5,542 patients with primary mPCa.

• The results showed that the median OS elevated from 2.3 years in 2004–2009 to 3.3 years in 2015–2018. 3-year OS improved from 41% in 2004–2009 to 51% in 2015–2018.

• The results showed that an earlier diagnostic period, a more advanced T stage, higher ISUP grade group, lower WHO status, and higher PSA levels were correlated with a lower CSS.

• The study found similar outcomes for the subgroup.